Newsroom

ScaleReady, in collaboration with Wilson Wolf, Bio-Techne, and CellReady, has launched a ‘G-Rex’ grant program aimed at advancing CGTs.

Industry leaders are uniting to drive the future of cell and gene therapy manufacturing. Experts like Josh Ludwig of ScaleReady are at the forefront of implementing automation and digital solutions to overcome complex challenges in the sector. From streamlining operations to accelerating time-to-market, these advancements are poised to revolutionize the industry.

The final installment of "The Top Line" series dives deep into the cutting-edge world of cell and gene therapy manufacturing. Join host Fraiser Kansteiner, Josh Ludwig and other industry experts as they explore innovative production approaches and discuss how to overcome the challenges of bringing these life-saving therapies to market.

CAR-T therapy has promise but manufacturing is slow and expensive. In this article, ScaleReady's Josh Ludwig suggests CAR-T manufacturing can learn from the auto industry's assembly-line approach to improve efficiency and make these therapies more accessible.

Drug Discovery World discusses the future of the cell and gene therapy sector with industry experts, including ScaleReady’s Josh Ludwig, who predict what to expect in 2024 and beyond.

In this edition of the Pharma's Almanac quarterly roundtable questionnaire, industry experts, including Josh Ludwig, Global Director of ScaleReady, discuss the increasing pressure to reduce time-to-market. The share strategies to accelerate product development and commercialization without compromising quality.

In this edition of the Pharma's Almanac quarterly roundtable questionnaire, industry experts, including Josh Ludwig, Global Director of ScaleReady, discuss how pharmaceutical and biopharmaceutical companies can demonstrate their commitment to ESG principles in manufacturing.

Key figures at Phacilitate’s Advanced Therapies Week emphasized the power of sharing knowledge to create standardized, scalable processes in cell and gene therapy manufacturing. ScaleReady is proud to embrace this approach, especially in our partnership with Luminary Therapeutics.

Decentralized manufacturing models, where therapies are produced closer to the patient show promise. But the path from research to this decentralized model, while maintaining rigorous Good Manufacturing Practice (GMP) compliance, is anything but easy. In a recent panel discussion, Josh Ludwig shed light on this complex transition.

While cell and gene therapy represent a captivating frontier, ongoing innovation and adaptation to Industry 4.0 principles are essential for progress. In this feature, experts, including Josh Ludwig, Global Director of ScaleReady, delve into the definitions of Industry 4.0 and its implications for the present and future of cell and gene therapy manufacturing.

The upcoming year promises significant changes driven by historic successes and economic challenges in 2023. Notable events mark the industry's current juncture of innovation and adjustment. Industry leaders, including ScaleReady's Josh Ludwig, predict trends for 2024, including the transformative impact of AI in drug development and key regulatory changes to monitor.